Skip to main content
Fig. 1 | Retrovirology

Fig. 1

From: Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance

Fig. 1

Development of raltegravir resistance during raltegravir containing cART. Left hand panels: therapy history, HIV-1 RNA load, CD4+ cell count and resistance mutations detected by population sequencing of five patients receiving raltegravir therapy. All viral load measurements are marked by a solid black circle. The CD4+ cell counts are represented by open triangles. Samples analyzed by 454 deep sequencing are marked by colored circles. Resistance mutations detected by Sanger population sequencing are indicated in boxes. Only raltegravir resistance associated mutations are given. Right hand panels: evolution of resistance pathways, deep sequence analysis of the integrase core domain. Data was obtained by 454 pyrosequencing. Relevant resistance mutations are indicated at the respective nodes. Figures were generated using the nucleotide sequences and the redundancy-level for calling a variant was set at 80. No mutation information indicates wild-type amino acids. The size of each node is scaled to reflect the relative abundance and viral load at each time point and patient. Time points are indicated by color and correspond to the colored circles in the left hand panels: green is the baseline sample, blue the first sample after raltegravir therapy initiation; red is the second sample after raltegravir therapy initiation; black is the final sample after raltegravir therapy initiation. In patient 3 gold is another baseline sample predating the green sample

Back to article page